Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVSRIPO for Unresectable Melanoma
NCT03712358Phase 1Terminated
- Sponsor
- Istari Oncology
- Start
- Nov 2018
- Primary completion
- Mar 2021
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of lerapolturev in melanoma (5 cohorts), sponsored by Istari Oncology. Primary endpoint: Dose Limiting Toxicity at 24 months. Started Nov 2018; status: terminated.
02
Drugs
lerapolturev
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03712358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712358.